Trial Profile
Single escalating dose study of odanacatib in male Japanese volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Mar 2013
Price :
$35
*
At a glance
- Drugs Odanacatib (Primary)
- Indications Male osteoporosis; Postmenopausal osteoporosis
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics
- Sponsors Merck Research Laboratories; MSD KK
- 25 Mar 2013 New trial record
- 09 Mar 2013 Results presented at the 114th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.